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Abstract
Objective: The aim of this study was to investigate the effects of Rapamycin and 
Melatonin and their combination on deoxyribonucleic acid (DNA) methylation and 
cell proliferation in a estrogen receptor (ER)-negative breast cancer cell line (4T1 
cell line).
Materials and Methods: Four groups were designed with 4T1 cell line depending 
on drug combination (control, Rapamycin, Melatonin, Rapamycin + Melatonin) and 
their administration on different time periods (24, 48 and 72 hours). The drugs 
were administrated for 1, 2 and 3 times, respectively for these time periods. All 
samples were counted; immunostained (Ki67, DNA methyltransferase-1 (DNMT-1), 
DNA methyltransferase-3a (DNMT-3a) and p53) and real-time polymerase chain 
reaction (PCR) (DNMT-1 and DNMT-3a) was performed.
Results: The live/dead cell ratios were decreased in the Rapamycin and Rapamycin + 
Melatonin applied groups. Ki67 immunostaining showed that there was a decreased 
proliferation in the drug applied groups at 48th hours compared to the 24th hours. 
Also DNMT-1 expressions were decreased at 72th hour compared to that at 24th 
hour in all groups, especially in the Rapamycin administrated group. Adversely, 
DNMT-3a expression was increased at 72th hour compared to that at 24th hour 
in the groups, especially in the Rapamycin administrated group. Furthermore, an 
increased expression of p53 was seen in the drug given groups (highest in the 
Rapamycin applied group) when the time prolonged. Real-time RT-PCR analysis 
of DNMT-1 gene expression showed a decreased expression level in the Melatonin 
given group compared to the control group and an increased expression level was 
seen in the Rapamycin and Rapamycin + Melatonin administrated groups compared 
to the control group.
Conclusion: As a result, it was found that Rapamycin is more effective in 
metastatic breast cancer cells than Melatonin, both in the manner of cell viability 
and expressional changes of Ki67, DNMT-1, DNMT-3a and p53. 
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Introduction
Breast cancer is a frequently seen cancer type in 
women and is a public health problem which has an 
increasing incidence and mortality. Clinically, breast 
cancer can be classified into different subtypes: one 
of these classifications depends on hormone receptor 
profiles of breast cancer cells, which are estrogen 
receptor (ER), progesterone receptor (PR), and human 
epidermal growth factor receptor 2 (Her2-neu/HER2). 
This classification type includes; triple positive, 
luminal A, luminal B, Her2 type and triple negative 
breast cancer (TNBC: ER (-), PR (-), HER2 (-)) (1). TNBC 
accounts for 10-15% of all breast cancers and TNBC 
patients have poor treatment outcomes compared 
to the other breast cancers’ subtypes. The reason for 
this situation is that TNBC is more aggressive and does 
not have potential chemotherapeutic targets (2).
In mammals, cell proliferation is important for 
different processes, such as embryogenesis, growth 
and tumorogenesis (3). It is known that cancer cells 
have abnormal cell growth and proliferation pattern. 
Proliferation plays an important role in the treatment 
of cancer, as increased proliferation tendency of 
cancer cells causes poor prognosis (4). Disruption of 
deoxyribonucleic acid (DNA) methylation is the other 
hallmark of cancer. In general, DNA methylation is 
lower in tumor cells than in normal tissues, but in 
some part of the genome of cancer cells exhibits 
increased DNA methylation, such as CpG islands (5). 
The methylation is important for gene expression and 
the maintenance of genome integrity. In mammals, 
there are DNA methyltransferase (DNMTs) enzymes 
which establishes or maintains the methylation of 
DNA. Three enzymatically active mammalian DNMTs 
exist; DNMT-1, DNMT-3A and DNMT3B. Beside 
these, there is DNMT3L which is a regulatory protein 
lacking catalytic activity. DNMT-1 is reponsible for 
maintenance of methylation patterns during cell 
division, but DNMT3 is responsible for de novo 
methylation (6). 
Rapamycin and Melatonin are the drugs used for 
different types of cancer treatment, including breast 
cancer. Rapamycin is isolated from Streptomyces 
hygroscopicus and is an agent that blocks the 
mammalian target of Rapamycin (mTOR) (serine-
threonine kinases) pathway, which plays a key role in 
aggressive tumor growth, proliferation and survival 
(7). Melatonin (N-acetyl-5-methoxytryptamine), 
which is important for controlling biological rhythms, 
is an indolic hormone, mainly secreted by the pineal 
gland (8). It is shown that Melatonin plays a main role 
in tumor growth inhibition and motility decrement. 
Growth-inhibitory effects of Melatonin on breast 
cancer cells have been studied both in vivo and in 
vitro. It was found that the effects of Melatonin are 
more remarkable on ER-positive breast cancer cells, 
than in other types of cancers and the mechanisms 
of these effects are recently well known. It reduces 
the mitogenic response of cells and impairs estrogen 
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Özet
Amaç: Bu çalışmanın amacı; Rapamisin, Melatoninin ve bunların birlikte kullanımlarının, östrojen reseptörü (ER)-negatif meme 
kanseri hücre hattının (4T1 hücre hattı) deoksiribonükleikasit (DNA) metilasyonu ve hücre proliferasyonu üzerine olan etkilerini 
incelemekti.
Gereç ve Yöntemler: İlaç kombinasyonlarına (kontrol, Rapamisin, Melatonin, Rapamisin + Melatonin) ve bu ilaçların farklı zaman 
dilimlerinde (24, 48 ve 72 saat) uygulanmalarına bağlı olarak; 4T1 hücre hattı ile dört farklı grup oluşturuldu. İlaçlar, bu zaman 
dilimleri için sırasıyla; 1, 2 ve 3 defa uygulanmıştır. Tüm örnekler ile hücre sayımı, immun-boyama (Ki67, DNA metiltranferaz-1 
(DNMT-1), DNA metiltransferaz-3a (DNMT-3a) ve p53 antikorları ile) ve Real-time PCR (polimeraz zincir reaksiyonu) (DNMT-1 ve 
DNMT-3a primerleri ile) yapıldı.
Bulgular: Rapamisin ve Rapamisin + Melatonin uygulanmış olan gruplarda canlı/ölü hücre oranı düşüş göstermiştir. İlaç uygulanan 
gruplarda 24. saate kıyasla 48. saatte, Ki67 immun-boyaması ile proliferasyonda düşüş gözlenmiştir. Ayrıca DNMT-1 ekspresyonları; 
72. saatte, 24. saate kıyasla tüm gruplarda, özellikle rapamisin uygulanan grupta, düşüş göstermiştir. DNMT-3a ekspresyonu ise 
72. saatte, 24. saate kıyasla tüm gruplarda, özellikle rapamisin uygulanan grupta, artış göstermiştir. İlaç verilen gruplarda (en 
çok rapamisin uygulanmış olan grupta), ilaç uygulaması arttıkça ve süre geçtikçe artan p53 ekspresyonu gözlendi. DNMT-1 gen 
ekspresyonunun Real-time RT-PCR sonuçlarına göre, DNMT-1 gen ekspresyonu Melatonin uygulanan grupta kontrol grubuna kıyasla 
düşme eğilimi gösterirken, rapamisin ve Rapamisin + Melatonin uygulanan gruplarda kontrol grubuna göre artmıştır. DNMT-3a gen 
ekspresyonunun Real-time RT-PCR sonuçlarına göre ise, DNMT-3a gen ekspresyonu, tüm ilaç uygulanan gruplarda kontrol grubuna 
kıyasla artmıştır. 
Sonuç: Rapamisinin, metastatik meme kanseri hücrelerinde hem hücre canlılığı açısından hem de Ki67, DNMT-1, DNMT-3a ve p53’ün 
ekspresyonel değişimleri açısından Melatoninden daha etkili olduğu bulunmuştur.
52 Gökmen et al. The Expression Level of DNA Methyltransferase and Proliferation of Rapamycin, Melatonin and Rapamycin + Melatonin Treated 4T1 Cells
signaling pathway through both down-regulation of ER 
expression and inhibition of ER binding to the DNA (9). 
It has been shown that physiological concentrations 
of Melatonin (10-9 M) reduces the invasive capacity of 
ER-positive cancer cells; MCF-7 human breast cancer 
cells (10). Some studies have shown that Melatonin 
could stop the growth of ER-positive breast cancer 
cell line but not ER-negative breast cancer cells (11). 
Recently, it has been shown that Melatonin (1 mM) 
can reduce the cell viability of ER-negative breast 
cancer cells in vitro (12). 4T1 breast cancer cells are 
epithelial breast cancer cells in BALB/cfC3H mice and 
have similar tumor growth pattern and metastatic 
properties to human breast cancer. Also, they are a 
model for stage IV human breast cancer, resistant to 
6-thioguanine (ATCC® CRL-2539TM) and it is thought 
that they are TNBC cells (13). 
The aim of this study was to investigate the 
effects of prolonged Rapamycin, Melatonin and their 
combined administration on DNA methyltransferase, 
cell proliferation and tumor suppressor markers 
expression in the 4T1 breast cancer cell line.
Materials and Methods
Cell line and Cell Culture
As a breast cancer cell line, the 4T1 cell line (ATCC® 
CRL-2539™) was used. 4T1 cell line was obtained 
from Prof. Dr. H. Nur Olgun (Dokuz Eylül University, 
Institute of Oncology) and after several pasages, 
cells at the 24th pasage were used for this study. 
4T1 cells were grown according to the American 
Type Culture Collection (ATTC) recommendations. 
They were cultured in a complete medium, including 
DMEM (Lonza, Basel, Switzerland), 10% FBS (Gibco, 
Burlington, ON, Canada), 1% penicillin-streptomycin 
(Lonza, Basel, Switzerland) and 1% L-glutamine 
(Lonza, Basel, Switzerland), at 37 oC in a humidified 
5% CO2 incubator. The experiment was performed 
in 4 groups with 3 different time periods (24 h, 48 h, 
72 h) for each of them. And drug administration was 
done for 1, 2 and 3 times, respectively for these time 
periods.
• Group 1: Control group 
• Group 2: Rapamycin (100 nM) (BioShop, 
Burlington, ON, Canada) applied group 
• Group 3: Melatonin (1 nM) (Sigma, Munich, 
Germany) applied group 
• Group 4: Melatonin (1 nM) + Rapamycin (100 
nM) applied group
Main stocks of drugs were dissolved in ethanol 
(Sigma, St Louis, MO, USA) in the appropriate amount 
and then diluted with complete medium for the 
administration. The experiment was started with 
the same number of cells in all groups. The first drug 
administration time was considered as a zero time 
point. After 24 hours, group of 24-hour was analysed 
and second drug administration was done to 48-hour 
and 72-hour groups. At the 48 hours, group of 48 hour 
was analysed and third drug administration was done 
to 72-hour group.
Cell Counting
After 0.25% trypsin (Lonza, Basel, Switzerland) 
incubation, the cells in each group and time period 
were treated with trypan blue vital stain (Sigma, St 
Louis, MO, USA) to determine the ratio of live/dead 
cells and then counted with a haemocytometer. 
Immunohistochemical Staining
For immunohistochemistry, antibodies of Ki67 
(cell proliferation marker), DNMT-1, DNMT-3a (DNA 
methylation markers) and p53 (tumor supressor 
marker) were used. The slides were fixed with 
paraformaldehyde (Sigma, St Louis, MO, USA), treated 
with 3% hydrogen peroxide (Fluka, Buchs, Germany), 
solution with methanol (MERCK MILLIPORE, 
Darmstadt, Germany), and incubated with blocking 
solution (Invitrogen, Carlsbad, CA, USA) for 15 minutes 
at room temperature. Then, the slides were incubated 
with primary mouse monoclonal antibodies for Ki67 
(Thermo scientific, SP6, Waltham, MA, USA), DNMT-1 
(Bioss, Woburn, MA, USA), DNMT-3a (Bioss, Woburn, 
MA, USA) and p53 (Thermo scientific, Waltham, MA, 
USA) at 1:100 dilution for 2 hours at room temperature. 
This process was followed by a broad-spectrum 
secondary antibody (Invitrogen, Camarillo, CA, USA) 
administration for 1 hour, then, HRP-streptavidin 
reagent was applied (Invitrogen, Camarillo, CA, USA) 
for 30 minutes. After that, slides were stained with 
DAB (Diaminobenzidine, Invitrogen, Carlsbad, CA, 
USA). As a final step, the slides were counterstained 
with Mayer’s hematoxylin (Sigma, St Louis, MO, 
USA). All images were taken at 200× magnification. 
Five areas were examined from each slide, especially 
demarcated areas with brown staining. The intensity of 
immunohistochemical staining was graded as follows: 
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(-) no immunostaining, (+) weak, (++) moderate and 
(+++) strong. (-) and, (+) stained cells were considered 
as negatively stained. (++) and (+++) stained cells 
were considered as positively stained. Positively and 
negatively stained cells were counted and their ratio 
was calculated.
Total Ribonucleic Acid Extraction and Real Time 
Polymerase Chain Reaction Analysis
Real-time polymerase chain reaction (real-time 
PCR) was performed to determine the messenger 
ribonucleic acid (mRNA) levels of DNMT-1 and DNMT-
3a in 4T1 cells, treated with Rapamycin and Melatonin. 
Total ribonucleic acid (RNA) from 4T1 cells was 
extracted using TRIzol reagent (Invitrogen, Carlsbad, 
CA USA) and purified with columns and reagents 
(Quiagen) in accordance with the manufacturer’s 
instructions. Complementary deoxyribonucleic acid 
(cDNA) synthesis kit (Roche, Indianapolis, IN, USA), 
SYBR Green methodology and primers of DNMT-
1 and DNMT-3a were used to perform a real-time 
quantitative PCR (qPCR) (qRoche Lightcycler 480 
system) analysis. The housekeeping gene beta-actin 
was used as the internal control for gene expression 
normalization. The cycle threshold (Ct) indicates the 
number of cycles at which the fluorescent signal 
exceeds the threshold in qPCR. The mRNA levels 
were calculated using the comparative ΔCt method 
(target gene/reference gene). There was an inverse 
correlation between ΔCt value and gene expression 
level. The results were evaluated mathematically.
Results
Cell Counting
As a result of cell counting, it was found that live/
dead cell ratios decreased in Rapamycin applied 
(group 2) and Rapamycin + Melatonin applied (group 
4) groups as time progresses. The highest decrement 
in the live/dead cell ratio was seen in Rapamycin 
applied group. On the contrary, an increment in the 
live/death ratio was found in the control (group 1) and 
Melatonin applied (group 3) groups (Figure 1).
Immunohistochemical Staining
Immunohistochemical staining results were 
evaluated through rating the positive stained cells to 
negative stained cells. Ki67 expression was found to be 
decreased in the drug given groups and an increased 
expression of Ki67 protein was seen in the control 
group at 48 hours, compared to that at 24 hours. In 
addittion, Ki67 protein level was found to be decreased 
in the Rapamycin and Rapamycin + Melatonin applied 
groups compared to the control group at the 24 and 
48 hours. Also Melatonin applied group had decreased 
Ki67 expression at 48 hours compared to the control 
group (Table 1a, 1b) (Figure 2). DNMT-1 expression was 
decreased in all groups at 72 hours compared to the 
24 hours. The decrement in Rapamycin applied group 
was the highest. When the results were compared to 
the control group, it was seen that DNMT-1 expression 
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Figure 1. Live/dead cell ratio results: Group 2 (Rapamycin) 
and group 4 (Rapamycin + Melatonin) had a decrement, 
group 1 (control) and group 3 (Melatonin) had an 
increament in the live/dead cell ratio
Figure 2. Immunostaining density of Ki67: a) Control group 
(24 hour) b) Control group (48 hour), c) Rapamycin applied 
group (24 hour) d) Rapamycin applied group (48 hour), e) 
Melatonin applied group (24 hour) f) Melatonin applied 
group (48 hour), g) Rapamycin and Melatonin applied 
group (24 hour), h) Rapamycin and Melatonin applied 
group (48 hour), (magnification: x200). Ki67 expression 
was decreased in drug treated groups and increased in the 
control group at the 48 hours, compared to the 24 hours 
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level was increased in the drug given groups at 24 
hours, and at 72 hours, increased expression was seen 
in Rapamycin + Melatonin given group (Table 1 a-c) 
(Figure 3). As a result of DNMT-3a immunohistochemical 
staining, an increased expression was found in the 
groups at 72 hours compared to the 24 hours, especially 
in the Rapamycin administrated group. However, when 
the results were compared to the control group, it was 
seen that there was a decreased expression in the 
rapamaycin and Rapamycin + Melatonin administrated 
groups at 24 hours. Besides, there was an increased 
expression in the Melatonin applied group at 24 
hours compared to the control group. At the 48 hours, 
DNMT-3a expression level was increased in all drug 
given groups compared to the control group (Table 1 
a-c) (Figure 4). An increasing expression of p53 in the 
drug given groups was found at 48 hours and 72 hours 
compared to the 24 hours, especially in the Rapamycin 
administred groups. And there was an increased 
expression level of p53 in the drug given groups at 48 
and 72 hours compared to the control group (Table 1 
a-c) (Figure 5). 
Real-time Polymerase Chain Reaction
A. DNMT-1 Expression
DNMT-1 expression level was decreased in all 
groups as the time goes by. However, when the 
results were compared to the control group, it was 
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Table 1c. Groups of 72 hour (h), after 3 times drug administration
Groups (72 h)
Ki67
(+/-)
DNMT-1
(+/-)
DNMT-3a
(+/-)
p53
(+/-)
Control 0 6.53 11.94 0
Rapamycin (100 nM) 4.14 6.49 32.82 7.48
Melatonin (1 nM) 11.84 5.51 4.85 3.42
Rapamycin (100 nM) +
Melatonin (1 nM)
2.14 12.56 22.12 5.15
DNA: Deoxyribonucleic acid, DNMT-1: DNA methyltransferase-1, DNMT-3a: DNA methyltransferase-3a
Table 1 a-c. Immunohistochemical staining results; ratio of positive stained cells (+) to negative stained cells (-) for four 
markers; a) at the 24 hour, b) at the 48 hour and c) at the 72 hour
Tablo 1. a. Groups of 24 hour (h), after 1 time drug administration
Groups (24 h)
Ki67
(+/-)
DNMT-1
(+/-)
DNMT-3a
(+/-)
p53
(+/-)
Control 0.66 12.87 3.61 0
Rapamycin (100 nM) 0.46 20.54 1.31 0
Melatonin (1 nM) 2.41 18.62 4.5 0.71
Rapamycin (100 nM) +
Melatonin (1 nM)
0.38 22.31 2.83 0
DNA: Deoxyribonucleic acid, DNMT-1: DNA methyltransferase-1, DNMT-3a: DNA methyltransferase-3a
Table 1b. Groups of 48 hour (h), after 2 times drug administration
Groups (48 h)
Ki67
(+/-)
DNMT-1
(+/-)
DNMT-3a
(+/-)
p53
(+/-)
Control 0.71 0 1.64 1.28
Rapamycin (100 nM) 0.36 5.53 4.36 3.18
Melatonin (1 nM) 0.52 4.46 3.51 2.64
Rapamycin (100 nM) + Melatonin (1 nM) 0.37 1.97 13.84 2.76
DNA: Deoxyribonucleic acid, DNMT-1: DNA methyltransferase-1, DNMT-3a: DNA methyltransferase-3a
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found that DNMT-1 expression level was decreased 
in the Melatonin applied group at 24 and 72 hours. 
But DNMT-1 expression level was increased in the 
Rapamycin applied group at 24 and 48 hours compared 
to the control group. Also it was seen that DNMT-1 
expression level was increased in the Rapamycin + 
Melatonin applied group in all time periods compared 
to the control group (Table 2a).
B. DNMT-3a Expression
The expression level of DNMT-3a was decreased 
in all groups as the time goes by, but there was an 
increased expression in the Rapamycin + Melatonin 
applied group at 72 hours. However, when the results 
were compared to the control group, it was seen that 
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Table 2b. ΔCt value of DNMT-3a
Groups 24 hour 48 hour 72 hour
Control 0.2719 0.5262 1.3520
Rapamycin (100 nM) 0.1095 0.2072 0.9163
Melatonin (1 nM) 0.1500 0.2996 0.7393
Rapamycin (100 nM) +
Melatonin (1 nM) 0.1200 0.3234 0.0741
Table 2a, b. RT-PCR results; a) Relative expression ratio 
of DNMT-1 to reference gene and b) Relative expression 
ratio of DNMT-3a to reference gene
Tablo 2a. ΔCt value of DNMT-1
Groups 24 hour 48 hour 72 hour
Control 0.0150 0.0347 0.0443
Rapamycin (100 nM) 0.0128 0.0182 0.0830
Melatonin (1 nM) 0.0239 0.0340 0.0524
Rapamycin (100 nM) +
Melatonin (1 nM) 0.0137 0.0239 0.0285
Figure 3. Immunostaining density of DNA 
methyltransferase-1 (DNMT-1): a) Control group (24 hour), 
b) Control group (72 hour), c) Rapamycin applied group (24 
hour), d) Rapamycin applied group (72 hour), e) Melatonin 
applied group (24 hour), f) Melatonin applied group (72 
hours), g) Rapamycin and Melatonin applied group (24 
hour), h) Rapamycin and Melatonin applied group (72 hour) 
(magnification: x200). DNMT-1 expression was decreased 
at the 72 hours in all groups compared to the 24 hours 
Figure  4. Immunostaining density of DNA methyltransferase-
3a (DNMT-3a): a) Control group (24 hour), b) Control 
group (48 hour), c) Control group (72 hour), d) Rapamycin 
applied group (24 hour), e) Rapamycin applied group (48 
hour), f) Rapamycin applied group (72 hour), g) Melatonin 
applied group (24 hour), h) Melatonin applied group (48 
hour), i) Melatonin applied group (72 hour), j) Rapamycin 
and Melatonin applied group (24 hour), k) Rapamycin 
and Melatonin applied group (48 hour), l) Rapamycin 
and Melatonin applied group (72 hour) (magnification: 
x200). DNMT-3a expresison was increased at 72 hours 
in all groups compared to the 24 hours. Rapamycin and 
combined Rapamycin + Melatonin applied groups showed 
an increasing expression in each prolonged administration 
time. In the control and Melatonin applied groups a slight 
decreased expression at 48 hours compared to the 24 
hours, and an increased expresssion at 72 hours compared 
to 48 hours was seen
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DNMT-3a expression level was increased in all groups 
and in all time periods (Table 2b).
Discussion
Breast cancer is the most frequent cancer type 
in women and has an important rate of mortality 
(3). It has some routine prognostic markers; tumor 
size, grade, hormone receptor profile and genetic 
markers (14). Breast cancer is an important example 
of a hormone-dependent malignancy. The hormone 
estrogen has a role in the growth and differentiation of 
the normal mammary gland and the ductal branching. 
Despite this, the estrogen hormone has mammary 
carcinogenic effects as well (15). The cancer cells can 
acquire some properties which make them stronger 
than homeostasis mechanisms, such as unlimited 
proliferation, resistance to antiproliferative-apoptotic 
signals and escape from immune system (16). 
Besides, cancer cells undergo some changes in their 
genomic circuitry which allow them to survive. These 
changes may be activation of the protooncogenes or 
aberrant activation of tumor suppressor genes and 
pathways (17). Uncontrolled cell proliferation and 
disruption of methylation profiles of cells are the two 
hallmarks of the cancer (18,19). DNA methylation is 
an epigenetic event done by DNMTs. DNMT-1 has a 
role in maintenance of methylation profile, whereas 
DNMT-3A and DNMT3B carry out de novo methylation 
of genome (20). Changes in DNA methylation pattern 
of gene are associated with pathological conditions, 
such as cancer and autoimmune diseases (21). In this 
study, 4T1 (metastatic, 6-thioguanine-resistant) cell 
line was used and the effects of the drugs, Rapamycin 
and Melatonin, were investigated. The signaling 
pathways, which activate mTOR, a protein kinase 
that controls cell growth, proliferation and survival, 
were altered in different types of human cancers. It is 
already known that Rapamycin and its analogs block 
mTOR and, thereby, inhibit proliferation of cancer 
cells that leads to apoptosis (programmed cell death) 
(22). Rapamycin has effects on different types of 
cancer, such as rhabdomyosarcoma, neuroblastoma, 
glioblastoma, small-cell lung carcinoma, 
osteosarcoma, pancreatic carcinoma, renal cell 
carcinoma, Ewing’s sarcoma, prostate cancer, and 
breast cancer (23). Melatonin is another drug that 
has an oncostatic role on several kinds of tumors, 
but especially on hormone-dependent mammary 
(24). It is already known that Melatonin has negative 
effects on ER-positive breast cancer (25,26). Besides, 
recently it has been shown that Melatonin has a role 
in reducing tumor growth and cell proliferation, and 
inhibition of angiogenesis of ER (-) breast cancer 
cells (12). In our study, it was found that there was 
an increment in cell viability in the control group as 
expected. Likewise, an increment in cell viability was 
found in the Melatonin applied group. In addition to 
this, in the Rapamycin applied group and Rapamycin 
+ Melatonin applied group, there was a decrement 
in cell viability. The decrement in cell viabilty in the 
Rapamycin + Melatonin applied group was thought 
to be resulted from Rapamycin effects. These results 
indicate that Rapamycin has more adverse effect 
on cell viability than Melatonin. In accordance with 
these results, there are a lot of studies showing the 
adverse effects of Rapamycin even on triple-negative 
breast cancer cells when it is combined with some 
different agents as well (27,28). 
Ki67 is a cell-cycle associated non-histone protein 
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Figure 5. Immunostaining density of p53: a) Rapamycin 
applied group (24 hour), b) Rapamycin applied group (48 
hour), c) Rapamycin applied group (72 hour), d) Melatonin 
applied group (24 hour), e) Melatonin applied group (48 
hour), f) Melatonin applied group (72 hour), g) Rapamycin 
and Melatonin applied group (24 hour), h) Rapamycin 
and Melatonin applied group (48 hour), i) Rapamycin and 
Melatonin applied group (72 hour) (magnification: x200). 
In the drug given groups, an increasing density of p53 was 
found in each prolonged administration time
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required for cell proliferation and its level increases 
through mitosis. In this study, an increasing density of 
Ki67 in the control group at 48 hours showed us that 
there was an increment in proliferation in the cancer 
cells as expected. In contrast, there was a decrement 
in proliferation in all drugs applied groups in the 
time period of 48 hours. These results showed that 
drugs used in this study had adverse effects on cell 
proliferation of 4T1 breast cancer cells. Furthermore, 
these results are consistent with the cell counting 
results except for Melatonin applied group. In 
addition, DNMT-1 expression, which is one of the DNA 
methyltransferase and important for establishment of 
DNA methylation pattern, was decreased in all groups 
at 72 hours compared to 24 hours. Immunostaining 
of DNMT-3a showed an increased expression in all 
groups at 72 hours compared to 24 hours, which 
means that there were still ongoing methylations. 
Changes in methylation patterns of genomic DNA are 
generally assumed as an important factor of human 
cancers. As a result of these findings, it was thought 
that tumor suppressor genes may be activated after 
drug treatment due to the decrement in methylation 
and proliferation. 
P53 is an important tumor suppressor gene and its 
activation can lead to either cell cycle arrest and DNA 
repair or apoptosis. As a result of immunostaining, 
increased level of p53 protein in the prolonged drug 
given groups was found especially in Rapamycin and 
combined Rapamycin-Melatonin applied groups. In a 
previous study, it was shown that DNMT-1 expression 
represses the p53 expression in the pancreas to ensure 
the lineage specification of pancreatic progenitor cells 
through prohibiting the p53-dependent apoptosis 
(29). In another study, it was shown that DNMT-3a 
directly interacts with p53 through the c-terminal 
domain of p53 in vivo and in vitro. This interaction 
causes the repression of p53 transcriptional activity 
which does not require DNA methyltransferase 
activity (30). In accordance with these studies, in this 
study, it was found that changes in p53 levels were 
compatible with the changes in DNMT-1 and DNMT-
3a levels. 
Conclusion
In this study, the effects of Rapamycin, Melatonin 
and their combinations on metastatic breast cancer 
cell line were investigated. The results obtained 
from cell counting and immunostaining showed that 
Rapamycin is more effective on cell proliferation 
and methylation of 4T1 cells. Besides, these effects 
became more prominent when the treatment period 
was prolonged. As a further study, searching for the 
expressional changes of other tumor suppressor 
genes’ and downstream targets of p53 such as p21 is 
needed.
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